Upstream Bio, Inc. (UPB) Research

Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.

Market snapshot

Symbol
UPB
Price
$6.25
Day change
+1.63%
Market cap
$340.1M
P/E ratio
-2.17x
52-week range
5.85-33.68
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$15.00

Recent news

  • Upstream Bio Lead Drug Pivotal Trial Plan Follows Strong Phase 2 Data

    The company reported a cash position of $341.5 million, expected to fund planned operations through 2027.

Peer companies

  • Amylyx Pharmaceuticals, Inc. (AMLX)
  • Intellia Therapeutics, Inc. (NTLA)
  • Novavax, Inc. (NVAX)
  • Pharvaris N.V. (PHVS)
  • Relay Therapeutics, Inc. (RLAY)
  • Syndax Pharmaceuticals, Inc. (SNDX)
  • Spyre Therapeutics, Inc. (SYRE)
  • Terns Pharmaceuticals, Inc. (TERN)

Recent insider activity

  • GRAY MICHAEL — S-Sale (853 shares) on 2026-06-16
  • Sutherland Everett Rand — S-Sale (2095 shares) on 2026-06-16
  • Houghton Adam — S-Sale (700 shares) on 2026-06-16
  • Deykin Aaron — S-Sale (895 shares) on 2026-06-16
  • Ambrose Allison — S-Sale (477 shares) on 2026-06-16

Open Upstream Bio, Inc. (UPB) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.